News

Eris Lifesciences and Natco Pharma Team Up to Bring Semaglutide to India

Strategic alliance aims to launch generic semaglutide by March 2026 to address Type 2 diabetes care.

• By PharmaNews Live Desk
• New Delhi
• Feb 24, 2026

News

In a significant development for India’s expanding metabolic care segment, Eris Lifesciences Limited and Natco Pharma Limited have announced a strategic partnership to commercialise semaglutide — a GLP-1 receptor agonist therapy used in the management of Type 2 diabetes and chronic weight management — in the Indian market.

The collaboration combines Eris’s established commercial presence and specialist network in diabetology with Natco’s manufacturing strength and regulatory expertise, particularly in complex formulations.

The partnership follows regulatory clearance from the Central Drugs Standard Control Organisation (CDSCO), which has granted Natco Pharma approval to manufacture and market a generic semaglutide injection in India. This approval lays the groundwork for a planned product launch in March 2026, targeting patients with inadequately controlled Type 2 diabetes as an adjunct to diet and exercise.

Industry analysts note that semaglutide has emerged globally as a transformative therapy due to its clinical benefits in glycaemic control and weight reduction, creating a rapidly growing market opportunity in India’s diabetes care landscape.

Eris Lifesciences, a major player in India’s branded formulations market, has been steadily expanding its diabetes franchise. The company said semaglutide represents a next-generation treatment that will strengthen its portfolio and support broader access to advanced metabolic therapies.

Amit Bakshi, Chairman and Managing Director of Eris Lifesciences, emphasised the strategic importance of the deal, stating:

“Semaglutide represents one of the most significant therapeutic advances in metabolic care in recent years. This partnership reflects our continued commitment to strengthening our diabetes franchise with innovative and high-impact therapies. With our strong commercial infrastructure and deep engagement in chronic therapies, we believe Eris is well-positioned to drive rapid adoption and enhance patient access in India.”

The planned introduction of semaglutide in India comes amid rising prevalence of Type 2 diabetes and increasing awareness around obesity and metabolic health. Experts believe that domestic commercial availability of more affordable generics could significantly broaden patient access to GLP-1 receptor therapies.

Eris’s share price reacted positively to the announcement, gaining ground in market trade, reflecting investor confidence in the company’s growth prospects tied to its diabetes care strategy.

Under the collaboration, Eris will leverage its strong specialist reach and commercial infrastructure, while Natco brings its manufacturing capacity and regulatory experience for semaglutide, aiming to accelerate market entry and uptake.

This alliance signals a deepening focus within India’s pharmaceutical sector on innovative therapies for chronic diseases, underscoring the commercial potential of metabolic care treatments domestically.